chr10-124790276-A-G
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2
The NM_212554.4(EEF1AKMT2):āc.173T>Cā(p.Ile58Thr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000688 in 1,453,834 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: not found (cov: 32)
Exomes š: 6.9e-7 ( 0 hom. )
Consequence
EEF1AKMT2
NM_212554.4 missense
NM_212554.4 missense
Scores
3
11
3
Clinical Significance
Conservation
PhyloP100: 7.29
Genes affected
EEF1AKMT2 (HGNC:33787): (EEF1A lysine methyltransferase 2) Enables protein-lysine N-methyltransferase activity. Involved in peptidyl-lysine methylation. Located in cytosol and nuclear body. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 2 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
EEF1AKMT2 | NM_212554.4 | c.173T>C | p.Ile58Thr | missense_variant | 2/7 | ENST00000368836.7 | |
EEF1AKMT2 | NM_001416243.1 | c.173T>C | p.Ile58Thr | missense_variant | 2/6 | ||
EEF1AKMT2 | NM_001304467.2 | c.-66T>C | 5_prime_UTR_variant | 2/7 | |||
EEF1AKMT2 | NM_001304468.2 | c.-66T>C | 5_prime_UTR_variant | 2/6 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
EEF1AKMT2 | ENST00000368836.7 | c.173T>C | p.Ile58Thr | missense_variant | 2/7 | 1 | NM_212554.4 | ||
EEF1AKMT2 | ENST00000464099.5 | c.173T>C | p.Ile58Thr | missense_variant, NMD_transcript_variant | 2/6 | 1 | |||
EEF1AKMT2 | ENST00000466270.5 | c.173T>C | p.Ile58Thr | missense_variant, NMD_transcript_variant | 2/7 | 1 | |||
EEF1AKMT2 | ENST00000652548.2 | c.173T>C | p.Ile58Thr | missense_variant | 2/6 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD4 exome AF: 6.88e-7 AC: 1AN: 1453834Hom.: 0 Cov.: 28 AF XY: 0.00000138 AC XY: 1AN XY: 723928
GnomAD4 exome
AF:
AC:
1
AN:
1453834
Hom.:
Cov.:
28
AF XY:
AC XY:
1
AN XY:
723928
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 16, 2022 | The c.173T>C (p.I58T) alteration is located in exon 2 (coding exon 2) of the METTL10 gene. This alteration results from a T to C substitution at nucleotide position 173, causing the isoleucine (I) at amino acid position 58 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D
M_CAP
Benign
D
MetaRNN
Uncertain
D
MetaSVM
Uncertain
T
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D
REVEL
Uncertain
Sift
Uncertain
D
Sift4G
Uncertain
D
Polyphen
P
Vest4
MutPred
Gain of disorder (P = 0.0093);
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.